TOT BIOPHARM International Company Limited reported unaudited consolidated earnings results for the six months ended June 30, 2021. For the period the company reported revenue of RMB 23,132,000 against RMB 13,030,000 a year ago. Operating loss was RMB 115,445,000 against RMB 128,363,000 a year ago. Loss for the period and attributable to the equity holders of the Company was RMB 115,005,000 or RMB 0.2 per basic and diluted share against RMB 129,183,000 or RMB 0.23 per basic and diluted share a year ago.